Literature DB >> 19330721

Design and validation of siRNAs and shRNAs.

Francesca Tilesi1, Piera Fradiani, Valentina Socci, Daniela Willems, Fiorentina Ascenzioni.   

Abstract

RNAi is a highly conserved intracellular mechanism, whereby dsRNA strands conduct post-transcriptional modulation of gene expression through a degradation or inhibition of the translation of target mRNA. Since its discovery in 1998, RNAi has been identified in many different organisms, including mammals, and this mechanism has provided new approaches for studies in cellular and molecular biology, functional genomics and drug discovery. siRNAs can be predicted by sequence and thermodynamic features, and the wide and proficient application of RNAi relies on the ability to select the most active siRNAs from among numerous predicted molecules. Recently, the first-generation prediction algorithms based on the characteristics of siRNAs, short hairpin (sh)RNAs and micro-(mi)RNAs have been improved by the use of computational models that account for the experimentally determined activities of large numbers of siRNAs/shRNAs and miRNAs. These second-generation algorithms differ from the first-generation algorithms in the computational tools that are used for the prediction of siRNA efficacy; although these new algorithms improve the design of effective siRNAs, they do not eliminate the requirement for an experimental evaluation of the activities of siRNAs. This review reports on the most significant second-generation algorithms of siRNA and shRNA characteristics, as well as on recently designed systems for the experimental evaluation of siRNA activities.

Mesh:

Substances:

Year:  2009        PMID: 19330721

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  11 in total

Review 1.  Artificial trans-acting small interfering RNA: a tool for plant biology study and crop improvements.

Authors:  Zhanyuan J Zhang
Journal:  Planta       Date:  2014-03-19       Impact factor: 4.116

2.  RBPJ inhibition impairs the growth of lung cancer.

Authors:  Qun Lv; Ronglin Shen; Jianjun Wang
Journal:  Tumour Biol       Date:  2015-01-15

Review 3.  Progress toward in vivo use of siRNAs-II.

Authors:  Garrett R Rettig; Mark A Behlke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

4.  Comparisons between chemical mapping and binding to isoenergetic oligonucleotide microarrays reveal unexpected patterns of binding to the Bacillus subtilis RNase P RNA specificity domain.

Authors:  Ruiting Liang; Elzbieta Kierzek; Ryszard Kierzek; Douglas H Turner
Journal:  Biochemistry       Date:  2010-09-21       Impact factor: 3.162

Review 5.  Genomic screening with RNAi: results and challenges.

Authors:  Stephanie Mohr; Chris Bakal; Norbert Perrimon
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

Review 6.  Gene interference strategies as a new tool for the treatment of prostate cancer.

Authors:  Mariarosaria Boccellino; Concetta Alaia; Gabriella Misso; Alessia Maria Cossu; Gaetano Facchini; Raffaele Piscitelli; Lucio Quagliuolo; Michele Caraglia
Journal:  Endocrine       Date:  2015-06-07       Impact factor: 3.925

7.  The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing.

Authors:  Walter R Strapps; Victoria Pickering; Gladys T Muiru; Julie Rice; Stacey Orsborn; Barry A Polisky; Alan Sachs; Steven R Bartz
Journal:  Nucleic Acids Res       Date:  2010-03-31       Impact factor: 16.971

8.  An RNAi in silico approach to find an optimal shRNA cocktail against HIV-1.

Authors:  María C Méndez-Ortega; Silvia Restrepo; Luis M Rodríguez-R; Iván Pérez; Juan C Mendoza; Andrés P Martínez; Roberto Sierra; Gloria J Rey-Benito
Journal:  Virol J       Date:  2010-12-20       Impact factor: 4.099

9.  An efficient algorithm for systematic analysis of nucleotide strings suitable for siRNA design.

Authors:  Ancha Baranova; Jonathan Bode; Ganiraju Manyam; Maria Emelianenko
Journal:  BMC Res Notes       Date:  2011-05-27

10.  Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2.

Authors:  Mattia Capulli; Antonio Maurizi; Luca Ventura; Nadia Rucci; Anna Teti
Journal:  Mol Ther Nucleic Acids       Date:  2015-09-01       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.